CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Model scores of the 29,894 trials active now.
Model score 76% for any early termination, 46% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 30% of the time (96 trials).
Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
How it ended
Terminated on 2018-12-17, after 2012-05-04 start.
Reason given by the sponsor: “enrollment”
The score above never used this outcome: finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.
Termination over time, as the model saw it at the start
Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2018-12-17. The rest of the way to 100% is still running.
From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.
What moved the score
-
Wording of the registration (title, summary, criteria) (raises risk) · Wording
Phrases that raised it: cellsmetastaticventricularor equalequal to
Phrases that lowered it: epithelialweekslargemodifyingacid -
Sponsor's past termination rate: 12.3% (raises risk) · Sponsor's track record
-
Accepts healthy volunteers: No (raises risk) · Who can join
-
Phase: 1/2 (raises risk) · Design
-
Disease area, cancer: Yes (raises risk) · Disease area
-
Trials the sponsor started in the prior 2 years: 284 (raises risk) · Sponsor's track record
-
Drug's FAERS reports with a death: 28.9% (raises risk) · Drug's FDA history
-
Minimum age: 18 (raises risk) · Who can join
-
Drug's FAERS reports marked serious: 96.9% (raises risk) · Drug's FDA history
-
Maximum age: 70 (lowers risk) · Who can join
-
Sponsor type: government (raises risk) · Sponsor's track record
-
Primary purpose: treatment (raises risk) · Design
-
Design: sequential (lowers risk) · Design
-
Collaborators: 0 (raises risk) · Design
-
Responsible party: principal investigator (lowers risk) · Design
-
Blinding: none (raises risk) · Design
-
Disease area, respiratory: Yes (raises risk) · Disease area
Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.
The trial
Design
- Phase
- 1/2 (typical: 2)
- Number of arms
- 2
- Allocation
- non randomized (typical: randomized)
- Design
- sequential (typical: parallel)
- Primary purpose
- treatment
- Blinding
- none
- Has a data monitoring committee
- No (typical: 56% yes)
- Responsible party
- principal investigator (typical: sponsor)
- Collaborators
- 0
- Keywords listed
- 5 (typical: 1)
Who can join
- Minimum age
- 18
- Maximum age
- 70 (typical: 71)
- Sex
- all
- Accepts healthy volunteers
- No (typical: 9% yes)
Sponsor's track record
- Sponsor type
- government (typical: academic or other)
- Sponsor's past trials
- 594 (typical: 32)
- Sponsor's past termination rate
- 12.3% (typical: 9.9%)
- Trials the sponsor started in the prior 2 years
- 284 (typical: 19)
Drug's FDA history
- Drugs with FDA adverse-event history
- 3 (typical: 1)
- Drug has FAERS history
- Yes (typical: 64% yes)
- Drug's FAERS reports before start
- 29422 (typical: 2148)
- Drug's FAERS reports in the prior 12 months
- 6586 (typical: 412.5)
- Drug's FAERS reports marked serious
- 96.9% (typical: 85.6%)
- Drug's FAERS reports with a death
- 28.9% (typical: 15.9%)
Disease area and drugs
- Disease areas
- cancer, respiratory, digestive, urogenital, endocrine
- Drugs matched to FDA substances
- aldesleukin, cyclophosphamide, fludarabine
Typical values are among the trials active now. Sponsor and drug history are counted only up to this trial's start date.
Similar finished trials
- CAR T Cells in Mesothelin Expressing Cancers NCT03054298 · started 2017 · scored riskier than 63% of active trials completed
- SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma NCT01362790 · started 2011 · scored riskier than 82% of active trials completed
- Autologous Redirected RNA Meso-CIR T Cells NCT01355965 · started 2011 · scored riskier than 74% of active trials completed
- CART-meso in Mesothelin Expressing Cancers NCT02159716 · started 2014 · scored riskier than 66% of active trials completed
- T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer NCT01967823 · started 2013 · scored riskier than 99% of active trials completed
Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.